Hope Biosciences Receives FDA Approval to Commence Groundbreaking Stem Cell Clinical Trial for Alzheimer’s Disease
Hope Biosciences is a clinical stage biotechnology company that develops cell-based therapeutics for acute and chronic disease. In fact, they stated that the FDA has approved a Phase I/II clinical trial that will assess safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimer’s Disease. This study is done in collaboration with Altoida, Inc., a predictive digital biomarker company.
Quote from Hope Biosciences CEO
Donna Chang, is the President and CEO of Hope Biosciences. She made a public statement on their news:
“This study will utilize our proprietary core technology to deliver high quality, pure mesenchymal stem cells with standardized doses and multiple treatments. Our novel technology allows us to overcome the burdens of traditional cell therapy, such as inability to make enough cells to make a significant impact.”
“We can produce, on-demand, over 1,000 highly concentrated HB-adMSC treatments from a single tablespoon of the patient’s own fat tissue. This technology eliminates potential donor rejection and donor-to-donor variability. We expect HB-adMSCs to safely and effectively diminish the effects of Alzheimer’s Disease and provide patients more time with better cognitive function.”
Indeed, there is no treatment clinically proven to affect Alzheimer’s Disease or regain cognitive functions. Hope Biosciences believes they can create a therapeutic solution.
Moreover, chronic neurodegenerative diseases exhibit neuroinflammation which provokes amyloid plaques and tau tangles. Besides, Alzheimer’s Disease shows these variables also.
Advanced imaging techniques detect amyloid in the brain, which can be followed in serial imaging over time. Researchers apply behavioral assessments on memory tasks to determine disease progression.
Altoida, Inc. has developed a tool, combining augmented reality (AR), machine learning (ML) and active Digital Biomarkers to assess patient’s risk for Mild Cognitive Impairment (MCI) as a result of Alzheimer’s Disease (AD). In fact, the Altoida Neuro Motor Index (NMI), is a Medical Device which identifies (MCI) due to AD 6-10 years before visible symptoms and with 94% accuracy.
Furthermore, it takes no more than 10 minutes and is the world’s first cognitive measurement of micro errors with active digital biomarkers. All major global healthcare markets can already use their innovative product as it has been approved by FDA and CE.
“Altoida is at the forefront of a new era to leverage Artificial Intelligence and Machine Learning to assess brain health,” said Dr. Richard Fischer, CEO & President of Altoida Inc. “We are convinced, that digital biomarkers are the future and will lead to earlier diagnosis, prevention and better treatments for a wide range of brain diseases. Altoida stands for deepening our understanding of brain health and will have a transformative impact on medicine and society,” said CSO & Founder Dr. Ioannis Tarnanas.